Bladder Cancer Clinical Trials
Bladder Cancer clinical trials evaluate new drugs, immunotherapies, radiation approaches, and combination treatments for bladder Cancer. Corterve aggregates actively recruiting Bladder Cancer studies from the public ClinicalTrials.gov registry so you can browse them by location and eligibility. Many oncology trials enroll patients at different stages of disease, including newly diagnosed and previously treated. This is general information, not medical advice — review any study with your oncology care team before enrolling.
Recruiting Bladder Cancer studies
- Measuring Surgical Recovery After Radical CystectomyNCT03193970M.D. Anderson Cancer CenterBladder CancerStanford, California
- En-bloc Transurethral Resection of Bladder Tumor (En-bloc TURBT) Specimens Using a Redesigned Surgical Resectoscope DeviceNCT04235764National Cancer Institute (NCI)Bladder CancerBethesda, Maryland
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialNCT06770582PHASE2National Cancer Institute (NCI)Non-Muscle Invasive Bladder Urothelial CarcinomaTucson, Arizona
- A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)NCT07419295PHASE3Merck Sharp & Dohme LLCBladder CancerWashington D.C., District of Columbia
- Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder CancerNCT07480356PHASE3Protara TherapeuticsBladder (Urothelial, Transitional Cell) CancerQueen Creek, Arizona
- Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder CancerNCT06510374PHASE3Ferring PharmaceuticalsIntermediate Risk Non-Muscle Invasive Bladder CancerMobile, Alabama
- In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE TrialNCT06704191PHASE1, PHASE2Mayo ClinicNon-Muscle Invasive Bladder CarcinomaJacksonville, Florida
- Evaluation for NCI Surgery Branch Clinical Research ProtocolsNCT00001823National Cancer Institute (NCI)Synovial Cell CancerBethesda, Maryland
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing TumorsNCT06814496PHASE1, PHASE2University of ArizonaMelanomaGilbert, Arizona
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsNCT03866382PHASE2National Cancer Institute (NCI)Bladder AdenocarcinomaBirmingham, Alabama
- A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027)NCT06637423PHASE1, PHASE2Merck Sharp & Dohme LLCNon-Muscle Invasive Bladder CancerBakersfield, California
- Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment SupportNCT07048496NAAbramson Cancer Center at Penn MedicineBladder CancerPhiladelphia, Pennsylvania
Bladder Cancer trials by state
Bladder Cancer trials by metro
Frequently asked questions
- How do I find recruiting Bladder Cancer clinical trials?
- Browse the actively recruiting Bladder Cancer studies listed on this page, or take an assessment to see trials you may qualify for based on your profile.
- Are Bladder Cancer clinical trials free to join?
- Costs, travel support, and any payment for taking part vary by study. Ask the study team what is covered before you decide to join.
- Who can take part in a Bladder Cancer clinical trial?
- Each study has its own eligibility criteria (for example age, disease stage, and prior treatments). This page is general information and not medical advice; discuss any specific trial with your healthcare provider to confirm whether it is appropriate for you.